Physician profile
Aditi Choudhry
NPI 1427218908
$179,281.26
in general payments reported to CMS, 2019-2025
57 companies · $110K in 2025
The $110K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $777 · 2020: $542 · 2021: $5,493 · 2022: $584 · 2023: $6,475 · 2024: $56K · 2025: $110K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $112K · Consulting Fee: $30K · Travel and Lodging: $22K · Food and Beverage: $7,776 · Education: $308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $111,550.00 |
| Consulting Fee | $30,087.50 |
| Travel and Lodging | $22,163.97 |
| Food and Beverage | $7,776.49 |
| Education | $307.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $52,265.91 | 2019-2025 | Rybrevant, Carvykti, Erleada |
| Astellas Pharma US INC | $42,675.93 | 2024-2025 | Padcev, Xtandi, Vyloy |
| Pfizer INC. | $33,782.87 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $24,730.67 | 2019-2025 | Imfinzi, Calquence, Lynparza |
| Incyte Corporation | $4,988.48 | 2020-2025 | |
| Kyowa Kirin, INC. | $3,400.00 | 2025 | |
| Geron Corporation | $3,122.96 | 2025 | Imetelstat |
| Glaxosmithkline, LLC. | $3,076.59 | 2021-2025 | Jemperli, Zejula, Ojjaara |
| Genmab U.S., INC. | $1,606.10 | 2024-2025 | Epkinly |
| Aveo Pharmaceuticals, INC. | $1,365.00 | 2023 | Fotivda |
| Seagen INC. | $1,285.66 | 2020-2025 | Padcev |
| Janssen Global Services, LLC | $1,050.00 | 2023 | Erleada |
| Bayer Healthcare Pharmaceuticals INC. | $1,042.66 | 2020-2025 | |
| Beigene USA, INC. | $675.00 | 2024 | Brukinsa |
| E.R. Squibb & Sons, L.L.C. | $615.76 | 2019-2025 | Opdivo |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $515.34 | 2019-2023 | Kyprolis, Xgeva, Vectibix |
| Merck Sharp & Dohme LLC | $358.28 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Kite Pharma, INC. | $253.83 | 2020-2023 | Yescarta |
| Lilly USA, LLC | $225.41 | 2019-2024 | Verzenio, Jaypirca |
| Novartis Pharmaceuticals Corporation | $221.73 | 2021-2025 | |
| Celgene Corporation | $166.90 | 2019-2025 | Opdualag, Reblozyl |
| Daiichi Sankyo INC. | $159.92 | 2023-2025 | Enhertu, Injectafer |
| Array Biopharma INC | $142.69 | 2019-2024 | Mektovi, Braftovi, Lorbrena |
| Exelixis INC. | $141.49 | 2021-2025 | Cabometyx |
| Abbvie INC. | $139.47 | 2020-2025 | |
| Myriad Genetic Laboratories, INC. | $122.00 | 2024-2025 | Precisetumor |
| Pharmacyclics LLC, An Abbvie Company | $121.69 | 2019-2023 | Imbruvica, Epkinly |
| Genzyme Corporation | $109.09 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $81.99 | 2023 | |
| Tersera Therapeutics LLC | $69.70 | 2019 | |
| Eisai INC. | $63.59 | 2023-2025 | |
| Tactile Systems Technology INC | $50.74 | 2023-2024 | Entre Plus, Flexitouch Plus |
| Sobi, INC | $46.14 | 2022-2023 | |
| Syndax Pharmaceuticals, INC. | $41.45 | 2025 | |
| Deciphera Pharmaceuticals INC. | $40.08 | 2024-2025 | Qinlock, Romvimza |
| Recordati_rare_diseases_inc. | $38.77 | 2023-2025 | Enjaymo, Sylvant |
| Gilead Sciences, INC. | $38.74 | 2021-2023 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $38.16 | 2020-2023 | Iclusig |
| Eusa Pharma (US) LLC | $29.79 | 2020 | |
| Foundation Medicine, INC. | $29.74 | 2020 | |
| Springworks Therapeutics, INC. | $29.62 | 2024 | Ogsiveo |
| Octapharma USA, INC. | $27.16 | 2023 | Panzyga |
| Jazz Pharmaceuticals INC. | $25.85 | 2020 | |
| Servier Pharmaceuticals LLC | $24.69 | 2025 | |
| Adaptive Biotechnologies Corporation | $22.03 | 2025 | Clonoseq |
| Legend Biotech USA INC. | $21.55 | 2024 | |
| Genentech, INC. | $20.37 | 2019 | |
| Clovis Oncology, INC. | $19.73 | 2019 | |
| Rigel Pharmaceuticals, INC. | $19.65 | 2020 | |
| Myovant Sciences INC. | $19.47 | 2021 | |
| Novocure INC. | $18.78 | 2020 | |
| Taiho Oncology, INC. | $18.78 | 2023 | |
| Aadi Bioscience, INC. | $18.38 | 2025 | Fyarro |
| Sun Pharmaceutical Industries INC. | $18.22 | 2019 | |
| Organon LLC | $17.89 | 2023 | |
| Emd Serono, INC. | $14.66 | 2021 | |
| Epizyme, INC. | $14.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aditi Choudhry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.